Proteomics International (ASX: PIQ) secures a US patent protecting its PromarkerEndo endometriosis blood test through 2041, strengthening commercialisation and licensing opportunities.
Botanix (ASX: BOT) secures a major European patent milestone for Sofdra’s proprietary applicator technology, strengthening intellectual property protection and future licensing opportunities.
Saluda Medical (ASX: SLD) has received FDA approval for its CAP24 Surgical Paddle Lead, expanding the Evoke System into the US surgical spinal cord stimulation market and unlocking access to approximately 30% more procedures.
Echo IQ has secured up to A$20 million from Pro Medicus alongside a US commercial partnership. Here’s why the AI healthcare deal could reshape Echo IQ’s growth story.
BCAL Diagnostics has unveiled BREASTEST Monitor, a blood test showing 91% sensitivity and 95% NPV for breast cancer recurrence detection, targeting millions of survivors globally.
Memphasys (ASX:MEM) secured an exclusive supply agreement with Monash IVF Group to deploy its Felix™ sperm selection technology across Australia, marking a major commercial milestone.
Vitrafy (ASX: VFY) surged after US military-backed trial data showed its “No-Wash” blood preservation technology smashed global platelet recovery standards.
Pro Medicus and EOS strengthened their global positions with major healthcare imaging and defense infrastructure deals as enterprise software demand grows across international markets.
Pacific Edge rallies after a draft Medicare proposal restores coverage momentum for its Cxbladder cancer diagnostics in the United States.
Bioxyne shares surged after the company secured a $50 million German medicinal cannabis agreement and expanded into Costa Rica’s regulated cannabis market.
EMVision Medical Devices (ASX: EMV) has expanded its pivotal emu™ Brain Scanner trial to include acute ischaemia detection, broadening commercial potential and accelerating its FDA pathway.
Neuren Pharmaceuticals (ASX: NEU) reports US$101 million in quarterly DAYBUE sales as the Rett syndrome treatment continues gaining traction globally.
Proteomics International (ASX: PIQ) secures a US patent protecting its PromarkerEndo endometriosis blood test through 2041, strengthening commercialisation and licensing opportunities.
Botanix (ASX: BOT) secures a major European patent milestone for Sofdra’s proprietary applicator technology, strengthening intellectual property protection and future licensing opportunities.
Saluda Medical (ASX: SLD) has received FDA approval for its CAP24 Surgical Paddle Lead, expanding the Evoke System into the US surgical spinal cord stimulation market and unlocking access to approximately 30% more procedures.
Echo IQ (ASX:EIQ) has launched a new Mayo Clinic research collaboration to evaluate its AI cardiac risk platform in cancer patients, expanding its reach into the growing cardio-oncology market.
LTR Pharma (ASX:LTP) signs an exclusive agreement with Strive Pharmacy, giving ROXUS nationwide U.S. fulfilment capability across all 50 states ahead of commercial launch.
Imugene (ASX: IMU) secured FDA Fast Track Designation for azer-cel after reporting a 100% response rate in CLL/SLL patients and strong results in Marginal Zone Lymphoma.
Immutep secures a global licensing deal with Dr. Reddy’s for immunotherapy efti, triggering a 25 percent share price jump. Here’s what the partnership means for investors and upcoming clinical milestones.
4DMedical (ASX:4DX) lands a US$10m CT:VQ order commitment through Philips’ North American network. Learn how this breakthrough deal accelerates adoption, expands market reach, and reshapes the future of respiratory imaging.
Recce Pharmaceuticals (ASX:RCE) wins Family 4 patent in Hong Kong for RECCE® 327 and 529, expanding IP across Asia as Phase 3 trials continue in Indonesia. CEO James Graham explains the strategic importance and next steps.
4DMedical (ASX:4DX) secures Stanford University as its first U.S. CT:VQ™ customer post-FDA clearance, while AstraZeneca expands its lung screening partnership across Brazil.
Clarity Pharmaceuticals (ASX: CU6) has signed a copper-67 supply agreement with Nusano, bolstering its U.S. theranostic pipeline ahead of Phase III prostate cancer trials.
FDA grants De Novo to PainChek’s Adult App, creating a new device code and opening a US$100m U.S. LTC market, with wider home/hospital upside.
Orthocell secures Alberta & BC distributors, launches Remplir at ASSH Vancouver, targets Dec-quarter sales; cash-backed rollout to drive FY26 growth.
AVITA secures EU MDR CE Mark for RECELL GO, starting launches in Germany, Italy and the UK. Shares rise as investors weigh clinical data and rollout plans.
Neuren Pharmaceuticals (ASX: NEU) adds SYNGAP1-related disorder to its pipeline while earning A$14.7M in Q2 royalties from DAYBUE™. NNZ-2591 advances toward Phase 3. Read the latest update.
Rhythm Biosciences (ASX: RHY) announces strong performance for its ColoSTAT® cancer test across all CRC stages, eyes 2025 commercial launch pending final validation and NATA approval.
Neurizon Therapeutics (ASX: NUZ) advances NUZ-001 toward ALS trial entry after submitting FDA clinical hold response. Stock surges 19%. Learn more about the milestone update.
DorsaVi (ASX: DVL) achieves breakthrough RRAM integration in biomedical sensors, boosting speed, efficiency, and system longevity. Chairman Gernot Abl outlines vision for next-gen AI healthcare devices.
%252520Strikes%252520Bonanza%25252047%252520%252520Antimony%252520at%252520Sunday%252520Creek%252520as%252520Critical%252520Minerals%252520Story%252520Gains%252520Momentum.webp&w=3840&q=75)